Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin®) as a resuscitative agent
Dr Reddy’s partners with Pharmazz Inc to market Centhaquine as Lyfaquin, a resuscitative drug approved by the Drugs Controller General of India for hypovolemic shock in India and Nepal. The drug shows promise for septic shock management.
Special Protocol Assessment Agreement Reached Between Pharmazz, Inc. and the U.S. Food and Drug Administration for Phase 3 Clinical Trial of Sovateltide
Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has entered into a license agreement with Pharmazz Inc., (Pharmazz), a U.S. based biopharmaceutical company to commercialise a first-in-class innovative drug, Tyvalzi (Sovateltide) in India. Developed by Pharmazz for potential global use, Sovateltide is indicated for treating cerebral ischemic stroke.
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...
Pharmazz Inc. Announces Key Publications Regarding the Role of Adrenergic Receptors in Venous Blood Return to Treat Shock
OR AKIVA, Israel, Feb. 13, 2023 /PRNewswire/ -- EndoStream Medical today announced the first patient enrolled in the TORNADO-US clinical study in the U.S. This study evaluates the Nautilus™ Intrasaccular System, a revolutionary technology designed to treat cerebral aneurysms. The patient was treated at The Mount Sinai Hospital in New York, one of the largest and most respected hospitals in the nation.
WILLOWBROOK, Ill., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today presented positive results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke. Sovateltide demonstrated statistically significant and clinically meaningful improvements in multiple neurological outcomes in patients with acute cerebral ischemic stroke and was well tolerated. The trial results were presented in an oral session at the 14th World Stroke Congress in Singapore.